194 related articles for article (PubMed ID: 3783203)
21. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
Mansour EG; Gray R; Shatila AH; Tormey DC; Cooper MR; Osborne CK; Falkson G
J Clin Oncol; 1998 Nov; 16(11):3486-92. PubMed ID: 9817265
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
Oriana S; Coradini D; Sasso GM; Di Fronzo G
Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
[TBL] [Abstract][Full Text] [Related]
24. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
[TBL] [Abstract][Full Text] [Related]
25. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Gelber RD
Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
[No Abstract] [Full Text] [Related]
26. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.
Goldhirsch A; Gelber RD
Recent Results Cancer Res; 1989; 115():153-62. PubMed ID: 2696027
[No Abstract] [Full Text] [Related]
28. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Rossi A; Brambilla C; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772
[No Abstract] [Full Text] [Related]
29. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Fountzilas G; Stathopoulos G; Kouvatseas G; Polychronis A; Klouvas G; Samantas E; Zamboglou N; Kyriakou K; Adamou A; Pectasidis D; Ekonomopoulos T; Kalofonos HP; Bafaloukos D; Georgoulias V; Razis E; Koukouras D; Zombolas V; Kosmidis P; Skarlos D; Pavlidis N;
Am J Clin Oncol; 2004 Feb; 27(1):57-67. PubMed ID: 14758135
[TBL] [Abstract][Full Text] [Related]
30. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy.
Fowble B; Gray R; Gilchrist K; Goodman RL; Taylor S; Tormey DC
J Clin Oncol; 1988 Jul; 6(7):1107-17. PubMed ID: 3292711
[TBL] [Abstract][Full Text] [Related]
31. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
33. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O; Gelber S; Simoncini E; Castiglione-Gertsch M; Price KN; Gelber RD; Holmberg SB; Crivellari D; Collins J; Lindtner J; Thürlimann B; Fey MF; Murray E; Forbes JF; Coates AS; Goldhirsch A;
Breast Cancer Res Treat; 2009 Aug; 116(3):491-500. PubMed ID: 18953651
[TBL] [Abstract][Full Text] [Related]
34. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MH; Rudenstam CM; Collins J; Lindtner J; Cavalli F; Cortés-Funes H; Gudgeon A; Forbes JF; Galligioni E; Coates AS; Senn HJ
Ann Oncol; 1996 Mar; 7(3):245-50. PubMed ID: 8740787
[TBL] [Abstract][Full Text] [Related]
35. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer.
Ludwig Breast Cancer Study Group
J Clin Oncol; 1985 Aug; 3(8):1059-67. PubMed ID: 2862223
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
Pannuti F; Martoni A; Cilenti G; Camaggi CM; Fruet F
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):423-9. PubMed ID: 2968262
[TBL] [Abstract][Full Text] [Related]
38. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
[TBL] [Abstract][Full Text] [Related]
40. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
Ludwig Breast Cancer Study Group
N Engl J Med; 1988 Sep; 319(11):677-83. PubMed ID: 2901037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]